Online inquiry

IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9068MR)

This product GTTS-WQ9068MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IGF1R gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000875.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3480
UniProt ID P08069
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9068MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ292MR IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 177lu-DOTA-HH1
GTTS-WQ10979MR IVTScrip™ mRNA-Anti-CD79B, MCDS0593A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MCDS0593A
GTTS-WQ13452MR IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PRS-343
GTTS-WQ13964MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA REGN3470-3471-3479
GTTS-WQ12084MR IVTScrip™ mRNA-Anti-CD38, MOR-03087(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MOR-03087
GTTS-WQ2252MR IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ALX-0171
GTTS-WQ1623MR IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ACE-910
GTTS-WQ13169MR IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA PF-04518600
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW